The current study demonstrated that genetic and signaling aberrations in this Wilms tumor model ultimately lead to upregulation of glucose transporter (Glut1) expression and hexokinase activity, which explains increased 18F-FDG accumulation and enables the detection of early stage tumor lesions. The gene discussed is SLC2A1; the disease is neoplasm.